Keymed Biosciences, Inc. (HK:2162) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Keymed Biosciences Inc. has unveiled promising data from its phase I/II clinical study of CM336, a bispecific antibody for treating relapsed or refractory multiple myeloma, at the American Society of Hematology Annual Meeting. The study highlighted CM336’s manageable safety profile and encouraging preliminary efficacy, with significant response rates among patients. This development positions CM336 as a potential novel therapeutic option in the treatment landscape.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.